Home
News & Events
Leadership & Mission
Technology
Contact

Menu

Product Candidates Pipeline

Navrogen provides Research and Development services for its business partners to advance clinical product candidates for the treatment of various cancers. Current pipeline is shown below.

navrogen pipeline

NAVROGEN AND LEVENA ANNOUNCE COLLABORATION TO DEVELOP ANTIBODY DRUG CONJUGATES TO TREAT HUMORAL IMMUNO-SUPPRESSED CANCERS

Cheyney, PA, and San Diego, CA, February 4, 2020 -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, a company specialized in developing antibody drug conjugates (ADCs), announced today the expanded collaboration to develop ADCs targeting humoral immuno-suppressed cancers. ADCs developed under this collaboration combine Levena’s linker and cytotoxic payload chemistry expertise along with Navrogen’s cancer-targeting antibodies discovered using its proprietary Humoral Immuno Oncology (HIO) platform technologies.

NAVROGEN OPENS R&D OPERATIONS AT CHEYNEY UNIVERSITY

Cheyney, PA, January 31, 2020 -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced the opening of its R&D operations at the Cheyney University science center located in Chester County, PA. The move enables the company to expand its proprietary Humoral Immuno Oncology (HIO) technology discovery efforts to identify HIO-suppressed cancer types and development of therapeutic agents that can unlock a patient’s immune system to combat their cancer.

NAVROGEN INC. AND LONZA SIGN AGREEMENT TO USE LONZA’S GS GENE EXPRESSION SYSTEM^® FOR NAVROGEN’S ANTI-HIO TARGETING AGENTS

Philadelphia, PA (USA) and Basel (CH), 20 November 2019 -- Navrogen Inc. and Lonza Pharma & Biotech announced today that they have entered a licensing agreement for the production of Navrogen's biotherapeutics using Lonza’s GS Xceed Expression System. read more→

Navrogen's Mission

To be an industry leader in the area of humoral immuno oncology (HIO), a process whereby tumors produce factors that suppress the beneficial effects of patient’s immune systems against cancer as well as the therapeutic effects of antibody-based anti-cancer therapies.

NAVROGEN ENTERS INTO CRADA WITH THE U.S. NATIONAL CANCER INSTITUTE TO DEVELOP AGENTS TO OVERCOME TUMOR-MEDIATED IMMUNO-SUPPRESSION

Philadelphia, PA, October 1, 2019 -- Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI). The CRADA is focused on advancing antibody-based experimental medicines to targets associated with tumor-mediated immuno-suppression. read more→

NAVROGEN ANNOUNCES THE CLOSING OF $3.2M FUNDING TO SUPPORT ITS HUMORAL IMMUNO-ONCOLOGY PLATFORM DISCOVERY TECHNOLOGIES AND PRECLINICAL PIPELINE

Philadelphia, PA, September 17, 2019 -- Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing was led by Ben Franklin Technology Partners of South Eastern Pennsylvania and a number of private investors. read more→

“Na vro” (να βρω) is Greek for “to find”

Did you know...

We at Navrogen are committed to finding solutions and applying them to next-generation biologicals. Finding these solutions is at the core our mission.

Copyright © 2020 Navrogen - All Rights Reserved

A SiteOrigin Theme